Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.40 |
| ▸ | EP300 | Q09472 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7118676 | 0.87 | SMN1; SMN2 (0.57) | IGF1RALDH1A1KMT2ASMN1; SMN2HTT | |
| SCHEMBL7253205 | 0.84 | IGF1R (0.80) | IGF1RALDH1A1POLBKMT2ASMN1; SMN2 | |
| SCHEMBL94996 | 0.82 | IGF1R (1.00) | IGF1RALDH1A1POLBKMT2ASMN1; SMN2 | |
| SCHEMBL7122223 | 0.81 | IGF1R (0.71) | IGF1RALDH1A1POLBKMT2ASMN1; SMN2 | |
| SCHEMBL14195909 | 0.80 | IGF1R (0.44) | IGF1RALDH1A1POLBKMT2ASMN1; SMN2 | |
| SCHEMBL172745 | 0.76 | IGF1R (0.64) | IGF1RALDH1A1POLBKMT2ASMN1; SMN2 | |
| SCHEMBL4494376 | 0.73 | IGF1R (0.79) | IGF1RALDH1A1POLBKMT2AHPGD | |
| SCHEMBL25295408 | 0.72 | SMN1; SMN2 (0.58) | IGF1RALDH1A1POLBKMT2ASMN1; SMN2 | |
| SCHEMBL5621143 | 0.72 | ALDH1A1 (1.00) | IGF1RALDH1A1POLBKMT2ASMN1; SMN2 | |
| SCHEMBL4193955 | 0.72 | ALDH1A1 (0.62) | IGF1RALDH1A1POLBKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003035616-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-05-01 | — | — | WO | claimed |
| US-20150093398-A1 | Methods and Compositions for Treating or Preventing Cancer | MERCK SHARP & DOHME (US) | 2015-04-02 | — | — | US | disclosed |
| US-20120058112-A1 | ANTIBODIES | MERCK SHARP & DOHME CORP. | 2012-03-08 | — | — | US | disclosed |
| US-20110262525-A1 | METHODS OF TREATMENT | SCHERING CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| WO-2003035616-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058112-A1 | ANTIBODIES | IGF1R, EGFR, ERBB3 | IGF1R 1/4885ALDH1A1 1627/4885POLB 2278/4885 |
| US-20110262525-A1 | METHODS OF TREATMENT | ASAH2, FOLH1, CD44 | IGF1R 2978/4885ALDH1A1 1200/4885POLB 966/4885 |
| US-20150093398-A1 | Methods and Compositions for Treating or Preventing Cancer | BRCA1, VHL, TP53 | IGF1R 4709/4885ALDH1A1 484/4885POLB 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.